These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38093030)

  • 1. Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden.
    Polyzoi M; Ekman M; Reithmeier A; Jacob J; Karlsson E; Bertranou E; Linderholm B; Hettle R
    Pharmacoecon Open; 2024 Mar; 8(2):277-289. PubMed ID: 38093030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Adjuvant Olaparib for Patients With Breast Cancer and Germline BRCA1/2 Mutations.
    Zettler CM; De Silva DL; Blinder VS; Robson ME; Elkin EB
    JAMA Netw Open; 2024 Jan; 7(1):e2350067. PubMed ID: 38170520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-Utility Analysis of Adjuvant Olaparib for Germline BRCA1/2-Mutated, High-Risk HER2-Negative Early Breast Cancer in Spain.
    Cedillo S; González-Domínguez A; Ivanova-Markova Y; López López R; López-Tarruella Cobo S; Peña Pedrosa JA
    Pharmacoecon Open; 2024 Nov; 8(6):887-896. PubMed ID: 39160415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
    Muston D; Hettle R; Monberg M; McLaurin KK; Gao W; Swallow E; Zhang S; Kalemaj I; Signorovitch J; Moore K
    Gynecol Oncol; 2020 Nov; 159(2):491-497. PubMed ID: 32951894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
    Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
    Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of Pembrolizumab in Combination with Chemotherapy as Neoadjuvant Treatment and Continued as a Single Agent Adjuvant Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer in Hong Kong.
    Kwong A; Leung R; Chan TC; Khandelwal A; Mishra K; Huang M
    Oncol Ther; 2024 Sep; 12(3):525-547. PubMed ID: 39037537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.
    Chang SH; Svensson M; Hsin-Min Wang G; Wang Y; Kang HR; Park H
    J Manag Care Spec Pharm; 2024 Sep; 30(9):942-953. PubMed ID: 39213142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.
    Geyer CE; Garber JE; Gelber RD; Yothers G; Taboada M; Ross L; Rastogi P; Cui K; Arahmani A; Aktan G; Armstrong AC; Arnedos M; Balmaña J; Bergh J; Bliss J; Delaloge S; Domchek SM; Eisen A; Elsafy F; Fein LE; Fielding A; Ford JM; Friedman S; Gelmon KA; Gianni L; Gnant M; Hollingsworth SJ; Im SA; Jager A; Jóhannsson ÓÞ; Lakhani SR; Janni W; Linderholm B; Liu TW; Loman N; Korde L; Loibl S; Lucas PC; Marmé F; Martinez de Dueñas E; McConnell R; Phillips KA; Piccart M; Rossi G; Schmutzler R; Senkus E; Shao Z; Sharma P; Singer CF; Španić T; Stickeler E; Toi M; Traina TA; Viale G; Zoppoli G; Park YH; Yerushalmi R; Yang H; Pang D; Jung KH; Mailliez A; Fan Z; Tennevet I; Zhang J; Nagy T; Sonke GS; Sun Q; Parton M; Colleoni MA; Schmidt M; Brufsky AM; Razaq W; Kaufman B; Cameron D; Campbell C; Tutt ANJ;
    Ann Oncol; 2022 Dec; 33(12):1250-1268. PubMed ID: 36228963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
    Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
    J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-utility analysis of adjuvant trastuzumab therapy for HER2-positive early-stage breast cancer in the Philippines.
    Genuino AJ; Chaikledkaew U; Guerrero AM; Reungwetwattana T; Thakkinstian A
    BMC Health Serv Res; 2019 Nov; 19(1):874. PubMed ID: 31752849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.
    Davie A; Traoré S; Giovannitti M; Pompilio G; Lambton M; Cakar E; Chatterjee A
    Glob Reg Health Technol Assess; 2023; 10():62-69. PubMed ID: 37811343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.
    Wu HL; Luo ZY; He ZL; Gong Y; Mo M; Ming WK; Liu GY
    Br J Cancer; 2023 Feb; 128(4):638-646. PubMed ID: 36564566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
    Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
    J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic
    Li N; Zheng H; Huang Y; Zheng B; Cai H; Liu M
    Front Pharmacol; 2021; 12():632818. PubMed ID: 33959007
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with
    Tan DS; Chan JJ; Hettle R; Ghosh W; Viswambaram A; Yu CC
    J Gynecol Oncol; 2021 Mar; 32(2):e27. PubMed ID: 33559410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
    Gelmon KA; Fasching PA; Couch FJ; Balmaña J; Delaloge S; Labidi-Galy I; Bennett J; McCutcheon S; Walker G; O'Shaughnessy J;
    Eur J Cancer; 2021 Jul; 152():68-77. PubMed ID: 34087573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    Zhan M; Zheng H; Yang Y; He Z; Xu T; Li Q
    Cancer Manag Res; 2020; 12():12919-12926. PubMed ID: 33364840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which Patients Do We Need to Test for BRCA1/2 Mutation? Feasibility of Adjuvant Olaparib Treatment in Early Breast Cancer-Real-World Data from Two Large German Breast Centers.
    Dannehl D; Engler T; Volmer LL; Tegeler CM; Fusshoeller J; Gabrysch E; Eissler K; Seller A; Grischke EM; Hahn M; Gruber I; Schochter F; Pfister K; Veselinovic K; Leinert E; Rack B; Fink V; Janni W; Brucker SY; Hartkopf AD; Schäffler H
    Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the Treatment of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
    Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
    Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.